LGVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Longeveron Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.39+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $43.61M
- P/E (TTM)
- –
- Dividend yield
- –
Longeveron Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Clinical trial revenue | $954.00K | $1.40M | $668.00K | $940.00K | 79.6% | -32.0% |
| Contract manufacturing revenue | $222.00K | $487.00K | – | – | 18.5% | -54.4% |
| Contract manufacturing lease revenue | $23.00K | $503.00K | – | – | 1.9% | -95.4% |
| MSCRF TEDCO - grants [Member] | – | – | – | $118.00K | – | – |
| National Institute of Health - grant [Member] | – | – | $41.00K | $164.00K | – | – |
| Grant revenue | – | – | $41.00K | $282.00K | – | – |
| National Institutes of Health Grant [Member] | – | – | $41.00K | – | – | – |
By region
From the segment and revenue-disaggregation notes of Longeveron's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.